The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review
出版年份 2019 全文链接
标题
The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review
作者
关键词
-
出版物
Immunotherapy
Volume 11, Issue 16, Pages 1409-1422
出版商
Future Medicine Ltd
发表日期
2019-10-17
DOI
10.2217/imt-2019-0087
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer
- (2018) Esmeralda Celia Marginean et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- The Impact of Microsatellite stability status in colorectal cancer
- (2018) Ruby Gupta et al. CURRENT PROBLEMS IN CANCER
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of Colon Cancer
- (2018) Alexander Stein et al. Oncology Research and Treatment
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers
- (2018) Georgia Ritchie et al. JAMA Oncology
- Immunotherapy for Merkel cell carcinoma: a turning point in patient care
- (2018) Isaac S. Chan et al. Journal for ImmunoTherapy of Cancer
- Adjuvant therapy in patients with completely resected non-small cell lung cancer - Current status and perspectives
- (2018) Robert Pirker et al. Clinical Lung Cancer
- Immunotherapy for Merkel Cell Carcinoma
- (2018) Kotaro Nagase et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- What pharmacotherapeutics should one use for early stage non-small cell lung cancer?
- (2018) Ciro Battiloro et al. EXPERT OPINION ON PHARMACOTHERAPY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
- (2018) David Stenehjem et al. OncoTargets and Therapy
- Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
- (2018) Rachel Ryu et al. Frontiers in Oncology
- Immune Checkpoint Inhibition in Head and Neck Cancer
- (2018) Martin David Forster et al. Frontiers in Oncology
- Is there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts
- (2018) T. Sharma et al. Current Oncology
- Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
- (2018) Vincenzo Di Nunno et al. Future Oncology
- Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma
- (2018) Nicole A Carreau et al. Future Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- (2017) Sacha Gnjatic et al. Journal for ImmunoTherapy of Cancer
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential role of immunotherapy in advanced non-small-cell lung cancer
- (2016) Ramon Andrade de Mello et al. OncoTargets and Therapy
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started